Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report

BACKGROUND: Immune checkpoint inhibitors are effective therapies for a wide range of malignancies. Their increased use has led to a wide range of immune-related adverse effects including skin, gastrointestinal, pulmonary, endocrine, cardiac, and neurologic complications. CASE PRESENTATION: We presen...

Descripción completa

Detalles Bibliográficos
Autores principales: Cham, Jason, Ng, Daniel, Nicholson, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165972/
https://www.ncbi.nlm.nih.gov/pubmed/34053457
http://dx.doi.org/10.1186/s13256-021-02858-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165972/
https://www.ncbi.nlm.nih.gov/pubmed/34053457
http://dx.doi.org/10.1186/s13256-021-02858-7

Ejemplares similares